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1. Introduction
Kidney transplantation is considered the treatment of choice for patients with end-stage renal
disease, and is associated with improved survival, better quality of life and reduced costs when
compared with dialysis.[1, 2] However, the renal transplantation waiting list is forever
growing, out of proportion to the number of donors.[2, 3] Therefore it is all the more crucial
to develop strategies to extend the life and functionality of every allograft.
Rejection is no longer considered as a primarily T-cell-mediated process. We are fast realising
that inadequate control of the humoral arm of a recipient’s immune system is the pathogenic
factor primarily responsible for allograft dysfunction and loss. The destructive power of anti-
Human Leucocyte Antigen (HLA) alloantibodies and their association with antibody-
mediated rejection (ABMR) has been demonstrated and compelling evidence exists to show
that donor-specific anti-HLA antibodies (DSAs) are largely responsible for the chronic
deterioration of allografts, and may be a major contributor to the entity of chronic allograft
nephropathy (CAN).
ABMR must now be considered to be a spectrum of diseases; which include indolent ABMR,
C4d-negative ABMR, and transplant arteriopathy— in which DSAs have significant patho‐
logical effect. Also it has been shown that arteriosclerosis is accelerated in ABMR.[4-11]
A dynamic and progressive process of injury and repair that ultimately contributes to failure
of the allograft is considered the hallmark of ABMR.[12]
It has been demonstrated that glomerular endothelial swelling, subendothelial widening, and
early glomerular basement membrane duplication (precursor lesions) appear in the first weeks
after transplantation in a substantial number of crossmatch-positive kidney transplant
recipients.[13] Thus suggesting that the process of chronic antibody-mediated changes
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(transplant glomerulopathy) may occur earlier than previously reported.[12, 13] In addition,
DSAs can emerge at any time after transplantation and need not be present prior to trans‐
plantation.[14] Another important issue is that DSAs may differ in terms of their pathogenicity
and so have varying prognosis. [14]
Currently, treatment options for ABMR are aimed at antibody reduction and the inhibition of
complement activation and injury. These include plasma exchange with low-dose IVIG, high-
dose IVIG and rituximab for antibody reduction, and high-dose IVIG for complement and C3
convertase inhibition and the absorption of complement activation fragments (such as C3a,
C5a and C4b). Eculizumab (monoclonal anti-C5 antibody) and inhibitors of C1 are likely to
show benefit in the prevention and treatment of ABMR.
Advances in B-cell-directed immunotherapeutics will have a considerable impact on DSA
production, and consequently ABMR and allograft loss.
This chapter reviews the current understanding of antibody mediated rejection, and details its
diagnosis, and treatments, both those established in current routine clinical practice and those
on the horizon.
2. Rejection
Over the past two decades, our thinking has changed from considering rejection as a primarily
T-cell-mediated process (one that is now increasingly better managed in the era of more potent
calcineurin inhibitors and broader use of T-cell depleting therapies), to the realization that
insufficient control of the humoral arm of a recipient’s immune system by current immuno‐
suppressive regimens is now the pathogenic factor primarily responsible for allograft dys‐
function and loss.[13, 15, 16] This has changed our perception about allograft losses which
were deemed to be caused by calcineurin inhibitor (CNI) toxicity and chronic allograft
nephropathy (CAN).
Furthermore, the growing incidence of transplantation across HLA and ABO barriers by using
desensitisation programs, but in the face of known DSAs, has led to increased incidence and
a wider variety of ABMR. We are now exposed to a greater spectrum of antibody-mediated
graft injury.
3. Donor Specific Antibodies (DSAs)
Great advances have occurred in solid organ transplantation since the pioneering observation
of Kissmeyer et al.[17] in the 1960s, of the deleterious impact of allo-antibodies in kidney grafts.
About three decades later, the team of Edmonton described rejection episodes following
kidney transplantation related to the presence of anti-HLA donor specific antibodies (DSA)
[18]. The presence of DSAs and positive crossmatches with donors has long been considered
a contraindication to proceeding with transplantation as ABMR and graft loss is highly likely
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to occur in such situations[4]. However, recent data by Montgomery et al.[19] demonstrated a
significant reduction in the risk of mortality among highly sensitized patients who underwent
desensitization and transplantation compared with a well-controlled group of patients who
remained on dialysis. These authors concluded that desensitization followed by living-donor
transplantation offered significant survival benefit and that the survival advantage more than
doubled by 8 years.
In addition to DSAs existing prior to transplant, it has been realised that they can emerge at
any time after transplant, thus mediating allograft injury [14]. These de novo DSAs are different
in their pathogenicity. They are active against class II HLA and are associated with a worse
prognosis than DSAs against Class I HLA [14].
DSAs can cause all types of ABMR, including chronic ABMR, otherwise known as transplant
glomerulopathy.[4, 5, 7-10, 20]
4. ABMR
The pathophysiology of ABMR is not fully understood, but is an area of rapidly expanding
research. Several different patterns of allograft injury have been realised. These are initiated
by DSAs which bind to HLA antigens or to other targets on the allograft endothelium.
As mentioned earlier, the pathogenicity of DSAs is influenced by the isotype of the heavy chain.
Therefore, if DSAs are complement activating (IgG1 and IgG3), by binding IgG and activation
of C1q the classic complement pathway is rapidly activated[21] resulting in rapid loss of graft.
Alternatively, DSAs can bind to endothelial cell targets and stimulate cell proliferation (NK
cells) or induce antibody-dependent cell- mediated cytotoxicity (ADCC) with interferon γ
release.[4, 21]
Antibodies can also bind to HLA and other targets and incompletely activate the complement
system (that is, no C5b-C9 membrane attack complex generation) without causing apparent
injury. This process is referred to as accommodation.[22, 23] In addition, the long-term lack of
ADCC may be related to IgG Fc polymorphisms that lead to the failure of activation of NK
cells through FcγR (CD16)-dependent pathways[24] thus creating a greater degree of difficulty
in assessing pathogenicity of DSAs.
Protocol biopsy studies have shown that substantial oscillations occur in a patient’s humoral
status during the first 12 months after kidney transplantation. These oscillations are charac‐
terized by fluctuations in DSAs, C4d deposition and scores for glomerulitis and/or capillaritis
in a dynamic and multidirectional fashion.[12] Hence, the new concept that allograft injury is
unlikely the result of a single episode of ABMR, but instead that it represents a dynamic process
of injury and repair that begins early after transplantation and continues, unabated, at varying
levels thereafter.[3, 12]
The most florid form of ABMR, hyperacute rejection, has been almost completely eliminated,
owing to greatly improved crossmatching techniques between recipients and prospective
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donors, particularly technologies such as flow-cytometry. These tests are much more sensitive
for detecting a problem due to potential DSAs than older methods such as cell-dependent
cytotocity (CDC). With the waning of hyperacute rejection, the different manifestations of
ABMR that have emerged are indolent ABMR and C4d –negative ABMR.
4.1. Indolent ABMR
Modern therapies can efficiently reverse acute renal dysfunction from ABMR, but they usually
fail to deplete antibody-secreting plasma cells from the spleen and bone marrow of allograft
recipients.[25] Hence, after a clinical episode of acute ABMR, DSAs remain in circulation and
cause slowly progressive microvascular abnormalities without acute compromise of graft
function, at least initially. This truncated form of antibody-mediated injury is called subclinical
or indolent ABMR. [26, 27]
4.2. C4d-negative disease
In 1991, Feucht and co-workers discovered peritubular capillary deposition of C4d, an inactive
product of the classic complement pathway [28] in the histology of cases of ABMR. This greatly
improved the understanding and diagnosis of ABMR. It was called the “footprint” of antibody
mediated tissue injury. It soon became a requisite to test for C4d in all transplant allograft
biopsies. However, it has been recognised over time that C4d may only be the tip of the iceberg
of the humoral process and that it was neither completely specific nor sufficiently sensitive for
the diagnosis of ABMR[12, 29, 30].
C4d negative ABMR usually occurs more than 12 months after transplantation, but can occur
acutely in highly sensitised patients with persistent DSAs (even after desensitisation).
There have been many theories put forth to explain the presence of microvascular inflamma‐
tion on biopsy and presence of DSAs in circulation, without any evidence of complement
deposition. One is the technical issues related to type of fixative used and different methods
of C4d detection. Another is that some DSAs are poor at fixing complement. Also, some believe
the existence of a complement-independent pathway.[4] Furthermore, it is thought that as a
result of treatment of high risk patients, the clinical and histological presentation of ABMR has
changed.[3]
4.3. Acceleration of arteriosclerosis
This phenomenon has been recognised for many decades. It is evidenced by monocytic and
lymphocytic inflammation of the intima, myofibroblast proliferation and extracellular matrix
deposition causing mild to severe intimal arteritis and compromise of the lumen. It is a major
component of graft rejection but thought to be cell mediated. However, in 2003 Banff criteria,
the v3 lesions have been classified to reflect probable ABMR. More and more, studies have
shown that even v1 and v2 lesions occur in ABMR.[31]
Studies suggest that in DSA-positive patients there is significant acceleration of arteriosclero‐
sis.[11] Pathological examination demonstrated that while there is active ABMR, the intima is
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hypercellular, laying down new collagen over older (usually originating from donor). Once
ABMR is brought under control, the myofibroblasts stop proliferating, and the intima is no
longer hypercellular. What is left behind is a lesion no different from simple arteriosclerosis
of aging. This is termed “transplant arteriopathy”.[11, 32]
Chronic Antibody Mediated Rejection First described in 2001[33], the natural history of
chronic humoral rejection is now well known.[12, 29, 34] The presence of DSAs activates the
classical complement pathway causing peritubular multilamination and transplant glomer‐
ulopathy. These gradually become irreversible and cause permanent graft dysfunction. The
main challenges are when to initiate treatment and how to treat it, as it may be too late to
slow or halt the progress of this injury.[34, 35]
5. Pathology of antibody-mediated rejection
Antibody-mediated rejection (ABMR) was described in the early 1990s but was not incorpo‐
rated into the Banff classification until 2001. Now, due to an expanding spectrum of clinical
disease, two phenotypes of acute antibody-mediated rejection have been postulated and the
chronic form of ABMR is recognized as a leading cause of late allograft failure. The histology
of acute and chronic ABMR remains non-specific however.
5.1. Acute antibody-mediated rejection
Three patterns of tissue injury reflect acute antibody-mediated damage. These are acute
tubular injury (Figure 1), inflammation of glomerular and/or peritubular capillaries (so-called
microcirculation inflammation) (Figure 2 and 3), and fibrinoid necrosis of arteries (v3 lesion)
(Figure 4). Microcirculation inflammation may include a TMA-like pattern as well. It is
immediately obvious that all three types are not specific for ABMR and may be encountered
in a variety of clinical settings in the transplanted kidney. For example, the acute tubular injury
pattern is similar to that produced by ischaemia and capillaritis can be seen in the setting of
acute tubular necrosis or acute cellular rejection.
For these reasons, it was recommended that histology be correlated with C4d immunomicro‐
scopy and donor-specific antibodies (DSA) status. The former is an inactive fragment, split
from its parent molecule C4b during activation of the classical complement pathway, but due
to covalent binding with the endothelium, able to persist at sites of complement activation.
This covalent binding can be demonstrated with immunoperoxidase or immunofluorescent
(Figure 5 and 6) techniques and serves as a marker of complement activation. Neither method
is sensitive enough to detect all cases of ABMR.
A positive C4d result on renal biopsy shows linear, circumferential endothelial reaction in peri‐
tubular capillaries by either method, although the immunoperoxidase signal may be less intense
by one grade. Interrupted, granular deposition is considered non-specific. Diffuse and focal line‐
ar reaction in peritubular capillaries appears to correlate with glomerulitis and presensitization
[36], however an important caveat is the ABO-incompatible renal allograft. In this situation, dif‐
fuse linear C4d may be seen in the absence of tissue injury and graft dysfunction.
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Figure 1. Acute tubular necrosis (ATN) in acute ABMR
Figure 2. Glomerulitis (infiltration of capillary loops by monocytes [white arrows])
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Figure 3. Peritubular Capillaritis (dilatation of capillaries and margination of monocytes [white arrows])
Figure 4. Fibrinoid necrosis of small arteries (v3 lesion)
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Figure 5. Diffuse C4d staining (immunoperoxidase method)
Figure 6. Diffuse C4d staining (immunofluorescence method)
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The most recent Banff meeting update highlights two major phenotypes of ABMR. The first
type appears early in the post-transplant period in a presensitized patient and is more likely
to be C4d-positive. The second type develops late post-transplant, is due to de novo DSA
development and is likely to be C4d-negative [36]. The second phenotype is an important factor
in late graft loss[37]. It appears that Class II HLA molecules may be responsible and that much
of the endothelial damage is mediated by NK cells and, to a lesser extent, monocytes and
neutrophils (antibody-dependent cell-mediated cytotoxicity (ADCC) [38].
5.2. Chronic antibody-mediated rejection
Microcirculation Injury
The term “chronic ABMR” does not relate to a particular time post-transplantation, but rather
to architectural remodelling which can affect all compartments of the biopsy. In addition,
active ABMR may be superimposed on these changes. (Figure 7)
Figure 7. Active chronic ABMR. Severe peritubular capillaritis is seen in the setting of interstitial fibrosis (ci) and tubu‐
lar atrophy (ct)
The hallmarks of chronic ABMR are transplant glomerulopathy (TG) and multilayering of
peritubular capillary basement membranes, with or without transplant arteriopathy (TA) and
interstitial fibrosis and tubular atrophy, indicating that the microcirculation is the main target
of humoral attack. Transplant glomerulopathy manifests as double contours in silver-stained
sections and is well demonstrated by electron microscopy (figure 8). There is widening of the
subendothelial space by flocculent material and eventual duplication of the glomerular
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basement membrane. It has been shown in protocol biopsies that ultrastructural changes of
endothelial cell injury such as cell activation and loss, can be detected within weeks of
transplantation [39], pre-dating more permanent changes like mesangial matrix expansion and
glomerular basement membrane duplication.
Figure 8. Electron microscopy showing a widened subendothelial space containing flocculent material (thick arrow).
Duplication of the glomerular basement membrane is present (thin arrows).
Despite its close correlation with DSA, TG may not be specific for chronic ABMR, with
significant numbers of TG cases reportedly due to hepatitis C and thrombotic microangiopathy
[40]. Superimposed active antibody-mediated injury produces endocapillary proliferation
and, together with double contour formation, a mesangiocapillary-like pattern in glomeruli
(Figure 9). This is not accompanied by immunofluorescence findings typical of that type of
glomerulonephritis and no diagnostic deposits are seen by electron microscopy.
The endothelium of peritubular capillaries can also display early ultrastructural evidence of
damage before remodelling of the basement membrane occurs. Moderate to severe lamination
(>5 layers of basement membrane) is seen in chronic ABMR whereas mild lamination (2-5
layers) may be due to causes other than antibody-mediated rejection in the transplant kidney
and is also seen in native renal disease [39].
A study by Sis and co-workers [41] found that approximately 40% of cases with transplant
glomerulopathy were C4d negative despite having circulating antibodies and showing high
endothelial cell-associated transcript (ENDAT) expression. ENDATs represent altered gene
expression due to the effects of alloantibody and are thought to be a sensitive indicator of
ABMR. This same study reported a high percentage of graft loss when both antibodies and
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high ENDAT expression were present; graft loss was even higher when the biopsies showed
diffuse C4d positivity as well. Although currently experimental, the detection of high EN‐
DAT expression may prove useful in cases with circulation DSA and C4d-positivity on biop‐
sy but lacking histologic evidence of tissue damage.
Figure 9. Active chronic ABMR. Glomerulitis is superimposed on changes of transplant glomerulopathy.
Vascular lesions
The lesion of Transplant Arteriopathy TA is characterized by expansion of the arterial in‐
tima by fibrous tissue and a variable amount of inflammation. Originally, TA was attrib‐
uted to  chronic  T-cell  mediated rejection (TCMR) but  it  more likely reflects  generalized
scarring seen in  the  aging kidney allograft,  the  causes  of  which include ABMR. A per‐
centage of v1 and v2 lesions, also previously thought to be result of TCMR, may also be
associated with DSA and microcirculation injury [31].
Scarring and hyalinosis
A cluster analysis of 234 indicated renal allograft biopsies by Sis and co-workers [31] revealed
an association amongst arteriolar hyalinosis (ah), interstitial fibrosis (ci), tubular atrophy (ct)
and transplant arteriopathy (cv). In the past, these features were thought to be the result of
chronic calcineurin inhibitor use but it appears that they are non-specific and may be encoun‐
tered in a variety of settings in the renal allograft, including ABMR. Arteriolar hyalinosis, in
particular, is commonly encountered in the aging kidney, hypertensive nephrosclerosis and
diabetic nephropathy.
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6. Treatment
There has been significant development of newer and more specific therapies for ABMR. These
are aimed at depleting B cells, antibodies and inhibiting complement, owing to the unique role
of antibody and effector molecules in the process of ABMR. The therapeutic options include
intensification of maintenance immunosuppression (e.g. tacrolimus and mycophenolate),
plasmapheresis/plasma exchange, intravenous immunoglobulin (IVIg), corticosteroids and
antilymphocyte antibodies. Rituximab, splenectomy, bortezomib, and eculizumab have also
emerged as adjunctive or experimental therapies.
6.1. IVIg
The mechanism of action and the optimal dose of IVIg that should be administered in ABMR
are poorly understood.[42], but it is thought to have an immunomodulatory effect. The
proposed beneficial properties include compliment inhibition, suppression of immunoglobu‐
lin synthesis.[43, 44] High dose IVIg inhibits C3 convertase and the ability to absorb comple‐
ment activation fragments (e.g. C3a,C5a and C4b).[45]
There have been retrospective studies reporting improved one year graft survival in cases of
steroid and antithymocyte resistant ABMR treated with protocols incorporating IVIg and
plasmapheresis/ plasma exchange.[46-49] The need to combine plasma exchange is however,
unclear.[42]
6.2. Plasma exchange/plasmapheresis
Plasma exchange removes antibodies from the circulation. In the case of ABMR it is thought
to be efficacious through the removal of DSAs. However, it does not suppress further pro‐
duction. In fact, it may stimulate rebound immunoglobulin production if used on its own. It
is hence necessary to use it in conjunction with strategies which target antibody production
(for example, the anti-CD20 monoclonal antibody rituximab). ABMR treatment protocols may
utilise plasma exchange depending upon the antibody titre, the affinity of the antibody for the
antigen, the dose of IVIg and use of other agents.[42]
6.3. Rituximab
This is a humanised mouse monoclonal antibody that targets CD20, which is expressed on the
majority of B cells. However, most plasma cells lack CD20 and are unaffected by Rituximab.
Hence, its role will be as an adjunctive treatment. A recent single centre study compared
outcomes in 24 cases of ABMR treated with either high dose IVIg (2g/kg for four doses) versus
plasmapheresis plus IVIg (100mg/kg) for four treatments followed by IVIg (2g/kg for four
doses) and two doses of rituximab (375mg/m2). Improved 3-year survival (92% vs. 50%) and
significantly reduced DSA at 3 months was observed in the plasmapheresis/IVIg/rituximab
group.[6] It has also been seen to be effective when used as part of desensitization protocol in
ABO- incompatible (ABOI) transplants, although there is concern over the cost of increased
infections in recipients of such transplants. One study reported \patients who received B-cell
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depletion with rituximab as an induction agent had significant reductions in DSA generation
and rates of chronic transplant glomerulopathy over 5 years compared with ABO-compatible
low-risk transplant recipients who did not receive rituximab.[50]
6.4. Eculizumab
Drugs that inhibit compliment and C1 are likely to show benefit in the prevention and
treatment of ABMR and currently they are many human trials being conducted to evaluate
their effect.[3, 51]
Eculizumab is an antibody against complement protein C5, and hence, inhibits the formation
of the membrane attack complex (MAC). It is approved for use in paroxysmal nocturnal
hemoglobinuria (PNH) and has had promising results in treatment and ongoing management
of atypical haemolytic uraemic syndrome, for which it has also recently been approved for
use. It is, however, and extremely expensive therapy. A single case reported the use of
eculizumab in combination with plasmapheresis/IVIg to rescue a renal allograft undergoing
severe ABMR, and showed significant reduction in C5b-C9 (MAC) complex deposition in the
kidney.[52]
6.5. Splenectomy
The role of splenectomy in treating ABMR is not yet known. Case reports have demonstrated
that it may be useful as a rescue treatment in severe ABMR.[53] Majority of its use has been in
preventing hyperacute rejection in ABOI transplants [54, 55]. There remains concern over the
increased infection risk in splenectomised patients, particularly due to encapsulated organ‐
isms, and vaccination against Meningococcus and Pneumococcus is warranted where possible
prior to splenectomy to mitigate this risk.
7. Conclusion
Significant progress has occurred in the understanding of ABMR. Diagnosis, classification and
treatment of this process have evolved greatly. However, standardisation of diagnostic tests
(DSA-testing), and development of evidence-based treatment guidelines is still lacking.
Currently, protocols are individualised among different centres and based largely on anecdotal
and/or local experience. ABOI and HLA desensitisation protocols (not detailed in this chapter)
also need to gain excellent long term results to justify the tremendous cost involved in order
to reduce the growing number of sensitised potential recipients on the waiting list. Paired
donor exchange programs, although fraught with major logistic as well as some ethical and
occasionally legal concerns, may be part of the solution to provide allografts to some of these
difficult-to-transplant individuals in order to improve their quality and quantity of life. Such
recipients, after successful transplantation, will be at increased risk of ABMR and will need
good monitoring and treatment strategies to enable successful long-term outcomes.
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